Status:
COMPLETED
Study to Evaluate the Immune Response of United Kingdom (UK) Infants Receiving DTaP/Hib/IPV, Meningococcal C Conjugate and Pneumococcal Conjugate Vaccines, Antibody Persistence and Responses to Booster Doses in the Second Year of Life
Lead Sponsor:
Public Health England
Collaborating Sponsors:
Institute of Child Health
National Institute of Biological Standards and Control
Conditions:
Meningococcal Infections
Pneumococcal Infections
Eligibility:
All Genders
7-12 years
Phase:
PHASE4
Brief Summary
The purpose of this study is: To assess whether there are differences in antibody persistence eight months post primary (pre-booster) or in responses to the booster with regard to the Meningococcal C...
Detailed Description
There is a well recognised benefit in reducing the number of injections included in an immunisation programme, particularly for infants where delivery of many antigens in the first few months of life ...
Eligibility Criteria
Inclusion
- No contraindications to vaccination as specified in the "Green Book" - Immunisation Against Infectious Disease, HMSO.
- Written informed consent obtained from the parent or legal guardian of the infant
- Infant aged no less than 7 weeks exactly, and no more than 11 weeks 6 days
Exclusion
- None
Key Trial Info
Start Date :
February 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 1 2010
Estimated Enrollment :
130 Patients enrolled
Trial Details
Trial ID
NCT00625677
Start Date
February 1 2008
End Date
March 1 2010
Last Update
March 22 2019
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Health Protection Agency
Gloucester, United Kingdom
2
Health Protection Agency
London, United Kingdom